Steel Partners' $16.75 INMD Bid: Merger-Arb Spread, Liquidation Zones & Small-Cap Med-Tech Repricing

Event Summary

According to a BusinessWire press release, Steel Partners Holdings L.P. has publicly offered to acquire InMode Ltd. (NASDAQ: INMD) for $16.75 per share in cash, framing it as a "Superior Proposal" over a competing CEO-led insider bid at $16.20 per share. Steel Partners holds an approximately 1.3% existing stake in InMode and is demanding the board immediately evaluate its proposal and run a transparent sale process. As reported by Investing.com, INMD shares surged in premarket trading on the news.

This is the third public bid salvo: Steel Partners initially offered $18.00 per share for a 51% stake in January 2026 (a ~29% premium to pre-rumor prices), which the board rejected in February. The current $16.75 offer includes an optional rollover allowing existing shareholders to roll up to 40% of InMode's equity into the Steel-controlled entity. The board has not yet formally accepted or rejected the latest proposal.

Leverage Impact Analysis

This is a classic merger-arbitrage and acquisition-repricing setup, and leverage amplifies both the opportunity and the risk significantly.

Worked Example — Long CFD at current spread: If INMD was trading near $15.85 pre-announcement (as noted in prior coverage) and is now pricing toward the $16.75 offer, that represents roughly a +5.7% move. A trader holding a 20x long INMD CFD on CoinUnited.io would see that translate to approximately +114% return on margin — but leverage cuts both ways.

Downside liquidation risk is the critical factor here. The deal is non-binding and contested. If the board rejects both bids and the process collapses, INMD could revert toward standalone fundamentals well below $15.85. A 20x long position opened near $16.50 would face liquidation if the stock falls ~5% — a realistic scenario if deal talks break down.

Key leverage scenarios to monitor:

• -Bull case: A bidding war pushes INMD back toward the prior $18.00 offer level — a ~7.5% upside from $16.75. At 20x leverage, that's ~150% gain on margin, but requires board cooperation and/or a third-party bidder.
• -Bear case: Both bids fail. Stock reverts below $15. High-leverage longs face forced liquidation cascades, potentially compressing the stock further.
• -Funding/carry consideration: On leveraged CFD positions held over multiple sessions, the cost of carry accrues. Given deal timeline uncertainty (no hard deadline disclosed), traders sizing up large leveraged positions should account for overnight holding costs eroding the merger spread.

This event fits squarely within the broader M&A acquisition wave theme, where contested bids create asymmetric leveraged setups — high reward, but with hard binary outcomes.

Cross-Market Impact

Small-cap med-tech / aesthetics peers: The $16.75–$18.00 valuation range now sets a live take-private benchmark for InMode's niche. Traders should monitor other small/mid-cap medical aesthetics and device names for re-rating — this is a classic cross-sector acquisition repricing signal. Per our guide on how buyout offers move markets, contested bids often lift entire peer groups by 2–5% as investors anticipate sector-wide M&A appetite.

iShares Russell 2000 ETF (IWM): INMD is a small-cap name. While this single deal won't move IWM materially, it reinforces private equity and activist appetite for small-cap healthcare — a mild sentiment positive for the index.

IBB (iShares Biotechnology ETF): Medical aesthetics is adjacent to biotech; the deal signals continued risk appetite from financial sponsors in healthcare innovation, modestly constructive for the broader healthcare/biotech space.

NASDAQ-100 (US100): Limited direct impact. INMD is not a Nasdaq-100 constituent. Macro spillover is minimal — this is a company-specific event.

Israeli tech/med-tech ADRs: As an Israel-based company, recurring foreign acquisition bids highlight ongoing international capital flows into Israeli med-tech names — a modest positive for any basket with Israeli tech exposure.

Trading Considerations

Key levels: The merger-arb spread sits between current market price and the $16.75 cash offer, with a theoretical ceiling near the prior $18.00 rejected bid if a bidding war materializes. Watch for any board response filings or Steel Partners deadline communications — these are the binary catalysts. Support near the pre-announcement range (~$15.85) acts as the downside anchor if the deal breaks. For those exploring acquisition arbitrage strategies, position sizing discipline is essential given the non-binding status of the offer.

Risk factors: Transaction uncertainty (board resistance, no hard acceptance deadline), regulatory approval risk (cross-border Israel/US deal), and potential fundamental deterioration if the process drags. Requires immediate market confirmation — monitor INMD's intraday price action vs. the $16.75 offer level as the primary signal of market-implied deal probability.

Start Trading on CoinUnited.io

Create Your Free Account → — Trade crypto, stocks, forex, indices, and commodities with up to 2000x leverage and zero fees.